Report : North America Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (Generic Drugs and Branded Drugs), Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), and Application (HIV, Hepatitis, Virus Influenza, Herpes, and Other Applications), and Country
Branded Drugs Segment Held Larger Share of Anti-Viral Therapies Market in 2019
According to our new market research study on “North America Anti-Viral Therapies Market Forecast to 2027 – Regional Analysis and Forecast – by Type, Mechanism of Action, and Application” the market is expected to reach US$ 31,092.80 million by 2027 from US$ 16,312.45 million in 2019; it is estimated to grow at a CAGR of 10.3% from 2020 to 2027. The report provides trends prevailing in the North America anti-viral therapies market and the factors driving the market growth along with those hindering it.
In 2019, the branded drugs segment accounted for a larger share of the market. Branded antiviral drugs are trusted more than the generic drugs. Further, robust research and development activities, increasing number of drug discoveries, and rising number of patents are likely to favor the growth of the branded antiviral drug market during the forecast period.
The growth of the North America anti-viral therapies market is mainly attributed to massive investments and new product launches. Further, the majority of players are engaged in business activities such as sales and research partnerships, innovation, and product approvals. For instance, in July 2020, Merck & Co. unveiled its plan to begin two large clinical trials of an experimental oral anti-viral therapy, MK-4482, for COVID-19 treatment, in September 2020. However,the high cost of drug development is the major factor hindering the market growth in North America.
Abbott; AbbVie Inc.; Bristol-Myers Squibb Company; Johnson and Johnson Services, Inc; Merck & Co., Inc, and Gilead Sciences, Inc. are among the leading companies operating in the North America anti-viral therapies market.
North America Anti-Viral Therapies Market, by Country, 2019 (%)
The Report Segments North America Anti-Viral Therapies Market as Follows:
North America Anti-Viral Therapies Market– by Type
- Branded Drugs
- Generic Drugs
- Nucleotide Polymerase Inhibitor
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
North America Anti-Viral Therapies Market – by Application
- Virus Influenza
North America Anti-Viral Therapies Market – by Country
Contact Person: Sameer Joshi
Email Id: email@example.com